Literature DB >> 8699233

Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas.

B S Chozick1, D L Benzil, E G Stopa, J C Pezzullo, N W Knuckey, M H Epstein, S D Finkelstein, P W Finch.   

Abstract

Meningiomas arise from the arachnoidal cells surrounding the brain and are one of the most common tumors of the central nervous system. These tumors are known to be hormonally modulated and may occur in association with breast carcinoma. Overexpression of the erbB-2 oncogene product and mutation of the tumor suppressor p53 gene are considered causal driving forces in the pathogenesis of adenocarcinomas of the breast. To determine whether abnormal expression of these genes also plays a role in the pathogenesis of meningiomas, we analyzed the expression of the erbB-2 and p53 proteins in 17 atypical and 35 typical meningioma tissue specimens by immunohistochemistry. The staining intensity was assigned a relative value of 0 to 5+, where 5+ denoted confluent immunoreactivity, 4+ to 1+ denoted varying degrees of focal positivity, and 0 denoted no evidence of staining. Levels of p53 and erbB-2 immunohistochemical staining were then correlated with tumor histology. For p53 immunoreactivity, typical meningiomas had a median staining score of 1.0, compared to 4.0 for atypical meningiomas (P < 0.0001, Mann-Whitney U test). For erbB-2 immunoreactivity, typical meningiomas had a median staining score of 5.0 compared to 1.0 for atypical meningiomas (P < 0.0001, Mann-Whitney U test). The inverse relationship between levels of erbB-2 and p53 immunoreactivity was found to be statistically significant (P < 0.0001, ANOVA). Expression of the erbB-2 protein was not associated with gene amplification or the presence of activating mutation in the transmembrane region of the protein. These findings may improve our understanding of the molecular events that occur in the neoplastic transformation of meningothelial cells. The patterns of erB-2 and p53 immunoreactivity may prove to be useful markers with which to identify potentially more malignant meningiomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699233     DOI: 10.1007/bf00177474

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  47 in total

1.  The relapsing course of certain meningiomas in relation to pregnancy and menstruation.

Authors:  E R BICKERSTAFF; J M SMALL; I A GUEST
Journal:  J Neurol Neurosurg Psychiatry       Date:  1958-05       Impact factor: 10.154

2.  Epithelial membrane antigen and cytokeratin expression by meningiomas: an immunohistological study.

Authors:  J M Theaker; K C Gatter; M M Esiri; K A Fleming
Journal:  J Clin Pathol       Date:  1986-04       Impact factor: 3.411

3.  The meninges in human development.

Authors:  R O'Rahilly; F Müller
Journal:  J Neuropathol Exp Neurol       Date:  1986-09       Impact factor: 3.685

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

5.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

6.  Intermediate filaments in meningiomas.

Authors:  W C Halliday; H Yeger; G F Duwe; M J Phillips
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

7.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

Authors:  P P Di Fiore; J H Pierce; M H Kraus; O Segatto; C R King; S A Aaronson
Journal:  Science       Date:  1987-07-10       Impact factor: 47.728

8.  Expression pattern of alpha-protein kinase C in human astrocytomas indicates a role in malignant progression.

Authors:  D L Benzil; S D Finkelstein; M H Epstein; P W Finch
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

9.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

Authors:  M F Press; C Cordon-Cardo; D J Slamon
Journal:  Oncogene       Date:  1990-07       Impact factor: 9.867

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  5 in total

1.  Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.

Authors:  M Ohkoudo; H Sawa; M Hara; K Saruta; T Aiso; R Ohki; H Yamamoto; E Maemura; Y Shiina; M Fujii; I Saito
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

2.  Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.

Authors:  Diana S Osorio; Jessica Hu; Carole Mitchell; Jeffrey C Allen; Joseph Stanek; Mari Hagiwara; Matthias A Karajannis
Journal:  J Neurooncol       Date:  2018-06-08       Impact factor: 4.130

3.  The role of MAPK signaling pathway in the Her-2-positive meningiomas.

Authors:  Zhaoyin Wang; Weijia Wang; Shan Xu; Shanshan Wang; Yi Tu; Yifeng Xiong; Jinhong Mei; Chunliang Wang
Journal:  Oncol Rep       Date:  2016-06-02       Impact factor: 3.906

4.  Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence.

Authors:  B R Ongaratti; C B O Silva; G Trott; T Haag; C G S Leães; N P Ferreira; M C Oliveira; J F S Pereira-Lima
Journal:  Braz J Med Biol Res       Date:  2016-03-18       Impact factor: 2.590

5.  Prognostic value of ErbB2/HER2 in human meningiomas.

Authors:  Magnus B Arnli; Theo L Winther; Stian Lydersen; Sverre H Torp
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.